Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of smac/DIABLO from the mitochondria
- 1 September 2006
- journal article
- research article
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 12 (3) , 133-142
Abstract
The synergistic interaction between proteasome inhibitors and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising approach to induce cell death in tumor cells. However, the molecular and biochemical mechanisms of this synergism have been proven to be cell type specific. We therefore focused our investigation on TRAIL-resistant colon carcinoma cells in this study. DNA fragmentation, mitochondrial membrane depolarization and increased caspase-3-like enzyme activity was exclusively induced only by combined treatment with proteasome inhibitors (epoxomicin, MG132, bortezomib/PS-341) and TRAIL. The expression level of anti-apoptotic proteins (XIAP, survivin, Bcl-2, Bcl-Xl), regulated by NF-κB transcription factor, was not effected by any of these treatments. TRAIL alone induced only partial activation of caspase-3 (p20), while the combination of TRAIL and proteasome inhibition led to the full proteolytic activation of caspase-3 (p17). Only the combination treatment induced marked membrane depolarization and the release of cytochrome c, HtrA2/Omi and Smac/DIABLO. Apoptosis-inducing factor (AIF) was not released in any of these conditions. These results are consistent with a model where the full activation of caspase-3 by caspase-8 is dependent on the release of Smac/DIABLO in response to the combined treatment. This molecular mechanism, independent of the inhibition NF-kB activity, may provide rationale for the combination treatment of colon carcinomas with proteasome inhibitors and recombinant TRAIL or agonistic antibody of TRAIL receptors. (Pathology Oncology Research Vol 12, No 3, 133–142)Keywords
This publication has 32 references indexed in Scilit:
- The Ubiquitin-Proteasome Pathway and Its Role in CancerJournal of Clinical Oncology, 2005
- Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitorsOncogene, 2005
- Proteasome inhibitor therapy in multiple myelomaMolecular Cancer Therapeutics, 2005
- The proteasome and MHC class I antigen processingBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2004
- The ubiquitin‐proteasome pathwayAnnals of Medicine, 2004
- The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cellsOncogene, 2003
- TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κBOncogene, 2003
- A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cellsCell Death & Differentiation, 2003
- Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase MaturationMolecular and Cellular Biology, 2003
- The role of nuclear factor-?b in the biology and treatment of multiple myelomaSeminars in Oncology, 2001